Pfizer Inc
NYSE: PFE
$26.21
+$0.38 (+1.5%)
Closing Price on November 29, 2024
PFE Articles
One strategy that has been popular each year as investors rebalance and make changes is the so-called Dogs of the Dow.
Published:
Last Updated:
Disney, Pfizer, General Electric, and McDonald's weighed on the DJIA Wednesday.
Published:
Last Updated:
Pfizer has just raised its payout by about 6% and more than doubled what it already had on its buyback plans.
Published:
Last Updated:
Intel, Microsoft, Pfizer, and United Technologies drove the DJIA higher Friday.
Published:
Last Updated:
Shares of Pfizer appeared to be headed for a new high after the company announced that the FDA had approved its treatment for adult patients with active psoriatic arthritis.
Published:
Last Updated:
Cellectis saw its shares make a handy gain early on Wednesday after the firm announced preliminary data from its two Phase 1 studies in conjunction with Pfizer.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
Published:
Last Updated:
Apple, Disney, Merck, and Pfizer were the leading gainers among the Dow 30 stocks on Monday. Bitcoin settled up 23% after its first trading session.
Published:
Last Updated:
A generic version of Viagra is coming to America, but will existing customers be willing to switch over to a generic version of the pill?
Published:
Last Updated:
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
Published:
Last Updated:
Disney, Intel, Pfizer, and Verizon led Tuesday's drop in the DJIA.
Published:
Last Updated:
One area to look at in this overbought and pricey market is pharmaceuticals. These five now are considered to be “deep value” plays at Merrill Lynch.
Published:
The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Published:
Last Updated:
Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.
Published:
Last Updated:
When Pfizer released its third-quarter earnings report before the markets opened on Tuesday, the results and guidance lived up to what analysts expected but weren't enough to placate investors.
Published: